InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,713.96
(
-0.28%
)
Post# of 316446
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

cintrix

Send PM Follow Ignore
Followers 364
Posts 113761
Boards Moderated 5
Alias Born 12/28/2000

cintrix

Member Level

Re: None

Monday, 10/22/2018 9:40:04 AM

Monday, October 22, 2018 9:40:04 AM

Post# of 316446
ADRO down 41% Thinly traded small cap Aduro Biotech (NASDAQ:ADRO) is down 24% premarket on light volume in apparent reaction to Merck's announcement of preliminary Phase 1 data on STING agonist MK-1454 at ESMO in Munich. The response rate was 0% in the monotherapy arm in patients with solid tumors or lymphomas.

Aduro's ADU-S100 is also a STING agonist. Preliminary Phase 1 data will be presented at the SITC annual meeting in early November.
https://seekingalpha.com/news/3399155-mercks-tepid-sting-data-pressures-aduro-biotech-24-percent-premarket
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up